View source for Mesothelioma Prognosis

{{#seo:
|title=Mesothelioma Prognosis: Scoring Systems, Prognostic Factors & Long-Term Survival
|description=Comprehensive guide to mesothelioma prognosis covering validated scoring systems (EORTC, CALGB, Brims, PLECH), BAP1 mutations, blood biomarkers, and factors that improve individual outcomes.
|keywords=mesothelioma prognosis, prognostic factors mesothelioma, mesothelioma scoring systems, BAP1 mesothelioma, mesothelioma long-term survival, PLECH score, mesothelioma life expectancy
|image=mesothelioma-prognosis.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-03-08
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Prognosis
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | Individual Prognostic Factors & Scoring Systems
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Median OS (Treated)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 12–21 months
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | BAP1 Carrier Median OS
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 5 years
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Best Scoring System
| style="padding:10px; border-bottom:1px solid #dee2e6;" | PLECH (AUC 0.70)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Under-50 5-Year Survival
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 39.2%
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Female 5-Year Survival
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 13.4% vs. 4.5% male
|-
| style="padding:10px; font-weight:bold;" | Key Prognostic Factors
| style="padding:10px;" | Stage, histology, PS, age, BAP1, NLR
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]</span>
|}

= Mesothelioma Prognosis =

== Overview ==

Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />

== Key Facts ==

{| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Mesothelioma Prognosis
|-
| style="padding:15px;" |
* '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />
* '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />
* '''Epithelioid vs. Sarcomatoid:''' 14–18 months vs. 4–8 months median survival; epithelioid 5-year survival approximately 14% vs. 4% for sarcomatoid<ref name="mattorney-epithelioid" /><ref name="mattorney-sarcomatoid" />
* '''Gender Difference:''' Women show HR 0.78 (22% reduced mortality risk) with 5-year survival of 13.4% vs. 4.5% for men<ref name="gender-survival" />
* '''Age Effect:''' Under 50: 39.2% five-year survival; 75+: 4.5% five-year survival — nearly 9-fold difference<ref name="factors-survival" />
* '''PLECH Score (2025):''' AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57)<ref name="plech" />
* '''NLR Biomarker:''' Neutrophil-to-lymphocyte ratio ≥5 carries HR 2.7 — 1-year survival drops from 60% to 26%<ref name="nlr-meta" />
* '''Peritoneal with CC-0:''' Complete cytoreduction achieves median 104 months (8.7 years) survival<ref name="mnet-hipec" />
* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
* '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />
|}

== What Factors Determine Mesothelioma Prognosis? ==

Mesothelioma prognosis is shaped by a combination of disease-related, patient-related, and treatment-related factors.<ref name="dandell-malignant" /> Unlike many cancers where staging alone drives prognosis, mesothelioma outcomes depend on a broader constellation of variables that clinicians assess collectively.

'''Disease-Related Factors''' include the anatomic site (pleural, peritoneal, pericardial, or testicular), histologic subtype (epithelioid, sarcomatoid, or biphasic), disease stage at diagnosis, and molecular characteristics such as BAP1 mutation status.<ref name="nci-treatment" /><ref name="mlc-stages" /> Peritoneal mesothelioma carries a fundamentally different prognosis than pleural disease, particularly when treated with cytoreductive surgery and HIPEC.<ref name="mlc-peritoneal" />

'''Patient-Related Factors''' encompass performance status (ECOG score), age at diagnosis, gender, nutritional status (serum albumin), and laboratory values including hemoglobin, white blood cell count, platelet count, lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR).<ref name="plech" /><ref name="brims" /> These measurable values form the basis of validated prognostic scoring systems.

'''Treatment-Related Factors''' include whether multimodal therapy is pursued, the completeness of surgical resection, access to immunotherapy, enrollment in clinical trials, and treatment at a high-volume specialized center.<ref name="mnet-centers" /><ref name="dandell-lawyers" /> Patients who receive treatment at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes.<ref name="nci-centers" />

{| style="width:100%; border:2px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px;" | '''ℹ Note:''' Prognosis is a statistical estimate based on groups of patients with similar characteristics — it does not predict what will happen to any individual. Some patients significantly outlive their predicted prognosis, particularly those with favorable molecular profiles such as BAP1 mutations.
|}

== How Do Prognostic Scoring Systems Predict Outcomes? ==

Four validated prognostic scoring systems have been developed specifically for mesothelioma, each combining multiple clinical variables to stratify patients into risk groups.<ref name="plech" /><ref name="eortc" /> These tools help oncologists set treatment expectations and guide decision-making about aggressive versus palliative approaches.

=== EORTC Prognostic Score (1998) ===

The European Organisation for Research and Treatment of Cancer score was the first validated mesothelioma prognostic model, developed from 204 patients across 5 phase II trials between 1984 and 1993.<ref name="eortc" />

'''Variables:''' Poor performance status, high white blood cell count, probable or possible histologic diagnosis, male gender, and sarcomatous histology.<ref name="eortc" />

{| class="wikitable" style="width:80%; margin:1em auto; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Prognostic Group
! style="background:#1a5276; color:white; padding:10px;" | Criteria
! style="background:#1a5276; color:white; padding:10px;" | 1-Year Survival
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Good prognosis
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2 or fewer of the 5 factors
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 40% (95% CI: 30–50%)
|-
| style="padding:10px;" | Poor prognosis
| style="padding:10px;" | 3 or more of the 5 factors
| style="padding:10px;" | 12% (95% CI: 4–20%)
|}

The EORTC score was externally validated at St. Bartholomew's Hospital (n=145), showing median survival of 19.2 months for the good-prognosis group versus 9.9 months for poor-prognosis. However, in contemporary analyses, its discriminatory power is limited (AUC 0.57).<ref name="calgb-validation" /><ref name="plech" />

=== CALGB Prognostic Score (1998) ===

The Cancer and Leukemia Group B score was developed from 337 patients across 7 phase II clinical trials, using regression tree analysis to identify 6 prognostic groups based on performance status, age, chest pain, dyspnea, platelet count, weight loss, LDH, hemoglobin, white blood cell count, and histologic subtype.<ref name="calgb-validation" /><ref name="mlc-treatment" />

The CALGB score was validated in a Leicester series (n=142) with results equivalent to the original data. Current AUC for 1-year overall survival prediction: 0.60.<ref name="plech" />

=== Brims Decision Tree Model (2016) ===

Developed from 482 cases with 174-case external validation (2005–2014), the Brims model uses a decision tree approach with five variables: weight loss, hemoglobin, serum albumin, performance status, and histology.<ref name="brims" /><ref name="bts-guideline" />

{| class="wikitable" style="width:100%; margin:1em auto; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Risk Group
! style="background:#1a5276; color:white; padding:10px;" | 18-Month Survival
! style="background:#1a5276; color:white; padding:10px;" | Median Survival
! style="background:#1a5276; color:white; padding:10px;" | Characteristics
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Group 1 (best)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 86.7%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 34.0 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | No weight loss, Hb >153 g/L, albumin >43 g/L
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Group 2
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Intermediate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Intermediate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | No weight loss, not meeting Group 1 lab criteria
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Group 3
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Intermediate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Intermediate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Weight loss present, PS 0–1, epithelioid histology
|-
| style="padding:10px;" | Group 4 (worst)
| style="padding:10px;" | 0%
| style="padding:10px;" | 7.5 months
| style="padding:10px;" | Weight loss present, PS 0–1, sarcomatoid histology
|}

The Brims model achieved a C-statistic of 0.761 (derivation) and 0.68 (validation) with 94.5% sensitivity. The British Thoracic Society endorses it as a clinical tool to consider at diagnosis.<ref name="bts-guideline" /><ref name="brims" />

=== PLECH Score (2025) ===

The newest and most accurate prognostic model, PLECH was developed from 262 patients at two cancer centers (2010–2023). Its name reflects the five weighted variables:<ref name="plech" />

* '''P'''latelet count (high): +2 points
* '''L'''DH (high): +1 point
* '''E'''COG ≥2: +1 point
* '''C'''hest pain at diagnosis: +2 points
* Non-epithelioid '''H'''istology: +1 point

Score range: 0–7 points. Optimal cut-off: 2.5.<ref name="plech" />

{| class="wikitable" style="width:80%; margin:1em auto; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Risk Group
! style="background:#1a5276; color:white; padding:10px;" | Median OS
! style="background:#1a5276; color:white; padding:10px;" | Median PFS
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Low risk (score <3)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 20.1 months
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 11.3 months
|-
| style="padding:10px;" | High risk (score ≥3)
| style="padding:10px;" | 12.3 months
| style="padding:10px;" | 6.4 months
|}

The PLECH score achieved an AUC of 0.70 for 1-year overall survival prediction, outperforming both CALGB (0.60) and EORTC (0.57) in the same patient population.<ref name="plech" />

{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "We advocate for early case evaluation because prognostic data directly informs legal strategy. A patient's scoring system results and biomarker profile shape not only treatment planning but also the urgency of filing claims before applicable deadlines expire."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}

== What Role Do Blood Markers Play in Prognosis? ==

Several routine laboratory values serve as independent prognostic indicators in mesothelioma, many of which are incorporated into the scoring systems described above.<ref name="plech" /><ref name="brims" />

{| class="wikitable" style="width:100%; margin:1em auto; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Biomarker
! style="background:#1a5276; color:white; padding:10px;" | Direction
! style="background:#1a5276; color:white; padding:10px;" | Impact
! style="background:#1a5276; color:white; padding:10px;" | Evidence
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Neutrophil-to-Lymphocyte Ratio (NLR)'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NLR ≥5 = worse
| style="padding:10px; border-bottom:1px solid #dee2e6;" | HR 2.7; 1-year survival 26% vs. 60%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Meta-analysis, n=1,533<ref name="nlr-meta" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Platelet Count'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | High = worse
| style="padding:10px; border-bottom:1px solid #dee2e6;" | +2 points in PLECH score (highest weight)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | PLECH 2025<ref name="plech" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''LDH (Lactate Dehydrogenase)'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | High = worse
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Independent predictor; +1 in PLECH
| style="padding:10px; border-bottom:1px solid #dee2e6;" | PLECH 2025, CALGB<ref name="plech" /><ref name="calgb-validation" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Hemoglobin'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Normal/high = better
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Hb >153 g/L associated with Group 1 (best) prognosis
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Brims 2016, EORTC<ref name="brims" /><ref name="eortc" />
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Serum Albumin'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | High = better
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Albumin >43 g/L associated with best prognostic group
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Brims 2016<ref name="brims" />
|-
| style="padding:10px;" | '''White Blood Cell Count'''
| style="padding:10px;" | High = worse
| style="padding:10px;" | Leukocytosis independently predicts poor outcome
| style="padding:10px;" | EORTC, SEER<ref name="eortc" /><ref name="seer-14k" />
|}

These biomarkers are particularly valuable because they are measured through routine blood tests available at any medical facility and can be monitored throughout treatment to track disease trajectory.<ref name="mnet-life" />

== How Do BAP1 Mutations Affect Long-Term Survival? ==

Germline BAP1 (BRCA1-associated protein 1) mutations represent the most significant molecular prognostic factor identified in mesothelioma, conferring dramatically improved long-term survival.<ref name="bap1-7fold" /><ref name="dandell-treatment" />

In a landmark study comparing 23 mesothelioma patients with germline BAP1 mutations to 10,556 SEER controls:<ref name="bap1-7fold" />

* '''Actuarial median survival:''' 5 years (versus less than 1 year for SEER controls)
* '''5-year survival:''' 47% (95% CI: 24–67%) versus 6.7% (6.2–7.3%) in SEER
* '''7-fold improved long-term survival,''' independent of sex and age
* '''Peritoneal BAP1 carriers:''' Median survival of 10 years
* '''Carriers with second malignancy:''' Median survival of 10 years

BAP1 carriers tend to develop epithelioid histology, respond exceptionally well to platinum-based chemotherapy, and demonstrate significantly enhanced chemosensitivity compared to sporadic mesothelioma cases.<ref name="bap1-chemo" /><ref name="bap1-care" />

{| style="width:100%; border:2px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px;" | '''✓ BAP1 Tumor Predisposition Syndrome:''' BAP1-TPDS (OMIM #614327) is an autosomal dominant hereditary cancer syndrome. Clinical practice guidelines (2023) recommend genetic counseling and surveillance for carriers, including regular imaging for mesothelioma detection. Given the improved survival in BAP1-associated mesothelioma, surveillance may allow earlier intervention and better outcomes.<ref name="bap1-guidelines" />
|}

A 2022 review by leading researchers noted that a fraction of BAP1 carrier patients "actually live 10 to 20 years and probably will not die of mesothelioma."<ref name="bap1-care" /> This represents a fundamentally different disease biology with implications for treatment intensity, surveillance strategy, and long-term planning.

== What Factors Can Improve a Patient's Prognosis? ==

While mesothelioma prognosis depends partly on immutable factors like age and gender, several modifiable factors can meaningfully influence outcomes:<ref name="dandell-lawyers" /><ref name="mlc-treatment" />

'''Early-Stage Diagnosis:''' Stage I patients have 5-year survival of 33% versus 4% for Stage IV. Localized disease at SEER summary staging achieves 23% five-year relative survival.<ref name="acs-survival" /><ref name="mlc-stages" />

'''Treatment at a Specialized Center:''' A National Cancer Database analysis (n=1,307) demonstrated that high-volume facilities achieve lower 30-day readmission rates (4.6% vs. 6.1%, p=0.021) and lower 90-day mortality (10.0% vs. 14.6%, p=0.029) compared to lower-volume centers.<ref name="volume-outcomes" /><ref name="nci-centers" />

'''Multimodal Treatment:''' Patients receiving surgery achieve median overall survival of 15 months versus 8 months without surgery (SEER data). The combination of chemotherapy, surgery, and repeat chemotherapy has achieved 3-year survival rates of 65% in selected patient populations.<ref name="mnet-treatment" /><ref name="dandell-malignant" />

'''Immunotherapy Access:''' The CheckMate 743 trial demonstrated that nivolumab plus ipilimumab achieves median overall survival of 18.1 months versus 14.1 months with chemotherapy alone, with 28% of responders maintaining response at 3 years compared to 0% with chemotherapy.<ref name="fda-nivo" /><ref name="cm743" />

'''Clinical Trial Enrollment:''' Trial participants often receive cutting-edge treatments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care.<ref name="ct-gov" /><ref name="mlc-entity" />

'''Maintaining Performance Status:''' Good physical fitness (ECOG 0–1) is a prerequisite for most curative-intent therapies and is an independent predictor of survival across all validated scoring systems.<ref name="eortc" /><ref name="brims" /><ref name="plech" />

== Who Are Long-Term Mesothelioma Survivors? ==

Long-term survival in mesothelioma is generally defined as surviving 5 or more years after diagnosis. At the population level, approximately 12–15% of pleural mesothelioma patients and up to 65% of peritoneal mesothelioma patients reach this milestone.<ref name="mnet-life" /><ref name="lts-peritoneal" />

=== Characteristics of Long-Term Survivors ===

Analysis of published case series and National Cancer Database data reveals consistent patterns among mesothelioma long-term survivors:<ref name="lts-peritoneal" /><ref name="factors-survival" />

* '''Younger age:''' Under 50: 5-year survival 39.2%, 10-year survival 33.4%<ref name="factors-survival" />
* '''Female gender:''' Independent predictor of improved survival (HR 0.78)<ref name="gender-survival" />
* '''Epithelioid histology:''' Predominates among long-term survivors<ref name="seer-14k" />
* '''Multimodal therapy:''' Surgery plus chemotherapy plus/minus radiation is the most common treatment among survivors<ref name="dandell-treatment" />
* '''Complete cytoreduction:''' CC-0 resection critical, particularly for peritoneal disease — median survival 104 months with CC-0 versus 30 months with CC-1<ref name="mnet-hipec" />
* '''Good performance status:''' ECOG 0–1 at diagnosis<ref name="brims" />
* '''BAP1 germline mutation carriers:''' 47% five-year survival with molecularly favorable disease biology<ref name="bap1-7fold" />

In a NCDB analysis of 3,636 peritoneal mesothelioma patients, 17.8% (n=648) qualified as long-term survivors with a median survival of approximately 92 months.<ref name="lts-peritoneal" /> For peritoneal disease specifically, surgery plus HIPEC achieved the longest median overall survival (65.9 months) compared to surgery plus systemic therapy (38 months) or surgery alone (9.6 months).<ref name="lts-peritoneal" />

== How Does Age Affect Mesothelioma Prognosis? ==

Age at diagnosis is a continuous independent predictor of mesothelioma survival, with younger patients demonstrating dramatically better outcomes across all types and stages.<ref name="factors-survival" /><ref name="seer-14k" />

{| class="wikitable" style="width:100%; margin:1em auto; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Age at Diagnosis
! style="background:#1a5276; color:white; padding:10px;" | 1-Year Survival
! style="background:#1a5276; color:white; padding:10px;" | 3-Year Survival
! style="background:#1a5276; color:white; padding:10px;" | 5-Year Survival
! style="background:#1a5276; color:white; padding:10px;" | 10-Year Survival
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Under 50
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 68.6%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 47.1%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 39.2%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 33.4%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 50–64
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 54.9%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 23.7%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 15.3%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 8.1%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 65–74
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 38.1%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 11.8%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 6.4%
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2.7%
|-
| style="padding:10px;" | 75+
| style="padding:10px;" | 33.0%
| style="padding:10px;" | 9.3%
| style="padding:10px;" | 4.5%
| style="padding:10px;" | 1.7%
|}

<small>Source: NCI SEER database<ref name="factors-survival" /></small>

Patients under 50 have nearly 9-fold better 5-year survival (39.2%) compared to those 75 and older (4.5%). This disparity reflects both disease biology — younger patients more frequently have BAP1-associated disease and peritoneal location — and the ability to tolerate aggressive multimodal treatment including surgery.<ref name="bap1-case" /><ref name="mattorney-pleural" />

Young-onset mesothelioma (under 40) is more likely to be associated with germline BAP1 mutations, peritoneal rather than pleural location (especially in young women), or exposure to alternative mineral fibers such as erionite.<ref name="bap1-case" /><ref name="bap1-guidelines" />

{| style="width:100%; border:2px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px;" | '''⚠ Important:''' Regardless of prognosis, statutes of limitations for mesothelioma lawsuits typically range from 1 to 6 years from diagnosis and do not pause based on treatment outcomes. Even patients with favorable prognostic profiles should consult with experienced mesothelioma attorneys promptly to preserve all legal options.<ref name="dandell-case" /><ref name="mattorney-compensation" />
|}

== Frequently Asked Questions ==

=== What is the average prognosis for mesothelioma? ===

The average mesothelioma prognosis depends heavily on disease type, stage, and treatment. For pleural mesothelioma with active treatment, median overall survival is 12 to 21 months. Peritoneal mesothelioma treated with CRS/HIPEC can achieve median survival exceeding 50 months. Individual prognosis may differ significantly from averages based on the prognostic factors described on this page.<ref name="dandell-diagnosis" /><ref name="mnet-hipec" />

=== Can mesothelioma prognosis improve over time? ===

Yes. Treatment advances — particularly immunotherapy (nivolumab plus ipilimumab) and tumor treating fields (TTFields) — have meaningfully improved survival expectations since 2020. Additionally, patients with favorable prognostic profiles including epithelioid histology, early-stage diagnosis, and treatment at specialized centers consistently outperform population averages.<ref name="fda-nivo" /><ref name="mlc-treatment" />

=== What is BAP1 and how does it affect prognosis? ===

BAP1 is a tumor suppressor gene. Patients carrying inherited (germline) BAP1 mutations develop a molecularly distinct form of mesothelioma with dramatically better prognosis — median survival of 5 years compared to less than 1 year for population controls. These patients show enhanced sensitivity to platinum-based chemotherapy and are more likely to survive long-term.<ref name="bap1-7fold" /><ref name="bap1-chemo" />

=== What is the PLECH score? ===

PLECH is the newest validated mesothelioma prognostic scoring system (2025), using five weighted variables: Platelet count, LDH, ECOG performance status, Chest pain, and non-epithelioid Histology. Scores range from 0 to 7, with scores below 3 (low risk) predicting 20.1 months median survival versus 12.3 months for scores of 3 or higher. It outperforms both the CALGB and EORTC scores in predicting 1-year overall survival.<ref name="plech" />

=== Does gender affect mesothelioma prognosis? ===

Women with mesothelioma demonstrate approximately 50% better survival than men, with a hazard ratio of 0.78 for death and 5-year survival of 13.4% versus 4.5%. This difference may reflect hormonal factors, different exposure patterns (secondary versus occupational exposure), higher rates of epithelioid histology in women, and potentially different disease biology.<ref name="gender-survival" /><ref name="mlc-women" />

=== How does the neutrophil-to-lymphocyte ratio predict outcomes? ===

The NLR is a simple blood test ratio that serves as a powerful prognostic biomarker. An NLR of 5 or higher carries a hazard ratio of 2.7 for death, with 1-year survival dropping from 60% (NLR below 5) to just 26%. NLR can be monitored throughout treatment to track disease trajectory and treatment response.<ref name="nlr-meta" />

=== Does treatment at a specialized center improve prognosis? ===

Research demonstrates that treatment at high-volume mesothelioma centers is associated with shorter hospitalization, lower readmission rates (4.6% vs. 6.1%), and lower 90-day mortality (10.0% vs. 14.6%). NCI-designated cancer centers with dedicated mesothelioma programs provide access to clinical trials, multidisciplinary teams, and high surgical volumes that improve outcomes.<ref name="volume-outcomes" /><ref name="nci-centers" />

=== Should mesothelioma patients get genetic testing for BAP1? ===

Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and testing for patients with mesothelioma, particularly those diagnosed at younger ages, those with family history of mesothelioma or related cancers (uveal melanoma, renal cell carcinoma), and those with limited or no known asbestos exposure history. BAP1 status has implications for prognosis, treatment planning, and family member surveillance.<ref name="bap1-guidelines" /><ref name="bap1-case" />

== Quick Statistics ==

* '''12–21 months''' median overall survival for treated pleural mesothelioma patients<ref name="seer-14k" />
* '''5 years''' median survival for mesothelioma patients with germline BAP1 mutations versus less than 1 year for non-carriers<ref name="bap1-7fold" />
* '''47%''' five-year survival rate among BAP1 mutation carriers compared to 6.7% in SEER population controls<ref name="bap1-7fold" />
* '''39.2%''' five-year survival for patients diagnosed under age 50 versus 4.5% for those 75 and older<ref name="factors-survival" />
* '''13.4%''' five-year survival for women versus 4.5% for men — women have 22% lower mortality risk<ref name="gender-survival" />
* '''104 months''' median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC<ref name="mnet-hipec" />
* '''0.70 AUC''' achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model<ref name="plech" />
* '''2.7 hazard ratio''' for death when neutrophil-to-lymphocyte ratio exceeds 5, dropping 1-year survival from 60% to 26%<ref name="nlr-meta" />
* '''10.0% vs. 14.6%''' 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers<ref name="volume-outcomes" />

== Get Help ==

If you or a loved one has been diagnosed with mesothelioma, understanding your individual prognosis is a critical first step toward making informed treatment and legal decisions. Multiple prognostic factors can be assessed through routine medical evaluations to help guide your path forward.

'''Legal Resources:'''
* [https://dandell.com/ Danziger & De Llano] — Experienced mesothelioma attorneys offering free case evaluations. Call '''(866) 222-9990''' for a confidential consultation.<ref name="dandell-home" />
* [https://mesotheliomalawyersnearme.com/ Mesothelioma Lawyers Near Me] — Find qualified mesothelioma attorneys in your area and access the free case evaluation quiz.
* [https://www.mesotheliomalawyercenter.org/ Mesothelioma Lawyer Center] — Legal resources and attorney matching services for mesothelioma families.<ref name="mlc-home" />
* [https://mesothelioma.net/ Mesothelioma.net] — Patient resources, treatment information, and support services.<ref name="mnet-life" />

== Related Pages ==

'''Medical Information:'''
* [[Mesothelioma_Survival_Statistics]] — Population-level survival data and treatment outcome statistics
* [[Understanding_Your_Diagnosis]] — Guide to mesothelioma types, staging, and diagnosis
* [[Mesothelioma_Treatment_Centers]] — Specialized cancer centers with mesothelioma programs
* [[Clinical_Trials]] — Current research studies and enrollment opportunities
* [[CheckMate_743_Trial]] — Immunotherapy trial data for nivolumab plus ipilimumab

'''Quick Reference:'''
* [[Mesothelioma_Quick_Facts]] — Core statistics and essential data
* [[Veterans_Mesothelioma_Quick_Reference]] — VA benefits and military exposure data

'''Legal Resources:'''
* [[Mesothelioma_Claim_Process]] — Steps from diagnosis to compensation
* [[Statute_of_Limitations_by_State]] — State-by-state filing deadlines
* [[Asbestos_Trust_Funds]] — Trust fund information and filing guidance

== References ==

<references>
<ref name="seer-14k">[https://pmc.ncbi.nlm.nih.gov/articles/PMC4682765/ Determinants of Survival in Malignant Pleural Mesothelioma: A SEER Study of 14,228 Patients], ''PLOS ONE'', 2015</ref>
<ref name="bap1-7fold">[https://edrn.cancer.gov/data-and-resources/publications/25380601-2967-mesothelioma-patients-with-germline-bap1-mutations-have-7-fold-improved-long-term-survival/ Mesothelioma Patients with Germline BAP1 Mutations Have 7-Fold Improved Long-Term Survival], National Cancer Institute EDRN</ref>
<ref name="eortc">[https://pubmed.ncbi.nlm.nih.gov/9440736/ Prognostic Factors in Patients with Pleural Mesothelioma: The EORTC Experience], ''Journal of Clinical Oncology'', 1998</ref>
<ref name="plech">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12668723/ Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score], ''Oncology'', 2025</ref>
<ref name="brims">[https://pubmed.ncbi.nlm.nih.gov/26776867/ A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma], ''Clinical Cancer Research'', 2016</ref>
<ref name="calgb-validation">[https://pubmed.ncbi.nlm.nih.gov/10950889/ Validation of CALGB and EORTC Prognostic Scoring Systems], ''British Journal of Cancer'', 2000</ref>
<ref name="nlr-meta">[https://www.oncotarget.com/article/15404/ Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Mesothelioma: A Meta-Analysis], ''Oncotarget'', 2017</ref>
<ref name="gender-survival">[https://pubmed.ncbi.nlm.nih.gov/24928677/ Women with Malignant Pleural Mesothelioma Have a Threefold Better Survival Rate Than Men], ''Annals of Thoracic Surgery'', 2014</ref>
<ref name="bap1-chemo">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6500142/ Inherited Predisposition to Malignant Mesothelioma and Overall Survival Following Platinum Chemotherapy], ''Proceedings of the National Academy of Sciences'', 2019</ref>
<ref name="bap1-care">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9233126/ Medical and Surgical Care of Mesothelioma Patients and Their Relatives Carrying Germline BAP1 Mutations], ''Journal of Thoracic Oncology'', 2022</ref>
<ref name="bap1-guidelines">[https://www.nature.com/articles/s41431-023-01448-z Clinical Practice Guidelines for the Diagnosis and Surveillance of BAP1 Tumor Predisposition Syndrome], ''European Journal of Human Genetics'', 2023</ref>
<ref name="bap1-case">[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.966063/full Case Report: Mesothelioma and BAP1 Tumor Predisposition Syndrome], ''Frontiers in Oncology'', 2022</ref>
<ref name="factors-survival">[https://pmc.ncbi.nlm.nih.gov/articles/PMC6198263/ Factors Influencing Malignant Mesothelioma Survival], ''BMC Cancer'', 2018</ref>
<ref name="cm743">[https://pubmed.ncbi.nlm.nih.gov/33485464/ First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743)], ''The Lancet'', 2021</ref>
<ref name="lts-peritoneal">[https://pubmed.ncbi.nlm.nih.gov/40525260/ Characteristics of Long-Term Survivors with Peritoneal Mesothelioma], ''Annals of Surgical Oncology'', 2025</ref>
<ref name="volume-outcomes">[https://pubmed.ncbi.nlm.nih.gov/29748018/ Facility Volume and Postoperative Outcomes for Malignant Pleural Mesothelioma], ''Annals of Thoracic Surgery'', 2018</ref>
<ref name="bts-guideline">[https://www.brit-thoracic.org.uk/document-library/guidelines/mesothelioma/bts-guideline-for-the-investigation-and-management-of-pleural-mesothelioma/ BTS Guideline for the Investigation and Management of Pleural Mesothelioma], British Thoracic Society, 2018</ref>
<ref name="fda-nivo">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma], U.S. Food and Drug Administration, 2020</ref>
<ref name="nci-treatment">[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ) — Patient Version], National Cancer Institute</ref>
<ref name="nci-centers">[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>
<ref name="acs-survival">[https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html Survival Rates for Pleural Mesothelioma], American Cancer Society</ref>
<ref name="ct-gov">[https://clinicaltrials.gov/search?cond=Mesothelioma Mesothelioma Clinical Trials], ClinicalTrials.gov</ref>
<ref name="dandell-diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
<ref name="dandell-compensation">[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>
<ref name="dandell-malignant">[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma], Danziger & De Llano</ref>
<ref name="dandell-lawyers">[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref>
<ref name="dandell-treatment">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma Differences], Danziger & De Llano</ref>
<ref name="dandell-case">[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>
<ref name="dandell-home">[https://dandell.com/ Asbestos & Mesothelioma Lawyers], Danziger & De Llano</ref>
<ref name="mlc-stages">[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/stages/ Stages of Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="mlc-treatment">[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/treatment/ Mesothelioma Treatment Guide], Mesothelioma Lawyer Center</ref>
<ref name="mlc-peritoneal">[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>
<ref name="mlc-entity">[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="mlc-women">[https://www.mesotheliomalawyercenter.org/blog/new-study-shows-higher-survival-rate-among-women-mesothelioma/ Study Shows Higher Mesothelioma Survival Rates in Women], Mesothelioma Lawyer Center</ref>
<ref name="mlc-home">[https://www.mesotheliomalawyercenter.org/ Find Top Mesothelioma Attorneys], Mesothelioma Lawyer Center</ref>
<ref name="mnet-life">[https://mesothelioma.net/mesothelioma-life-expectancy/ Mesothelioma Life Expectancy and Survival Rate], Mesothelioma.net</ref>
<ref name="mnet-treatment">[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>
<ref name="mnet-hipec">[https://mesothelioma.net/heated-intraperitoneal-chemotherapy/ Heated Intraperitoneal Chemotherapy (HIPEC)], Mesothelioma.net</ref>
<ref name="mnet-centers">[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>
<ref name="mattorney-pleural">[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], MesotheliomaAttorney.com</ref>
<ref name="mattorney-epithelioid">[https://mesotheliomaattorney.com/mesothelioma/types/epithelioid/ Epithelial Mesothelioma], MesotheliomaAttorney.com</ref>
<ref name="mattorney-sarcomatoid">[https://mesotheliomaattorney.com/mesothelioma/types/sarcomatoid/ Sarcomatoid Mesothelioma Guide], MesotheliomaAttorney.com</ref>
<ref name="mattorney-compensation">[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], MesotheliomaAttorney.com</ref>
</references>

[[Category:Mesothelioma]]
[[Category:Prognosis]]
[[Category:Medical Information]]
[[Category:Survival Statistics]]
[[Category:BAP1]]
[[Category:Prognostic Scoring Systems]]
[[Category:Treatment]]